Semaglutide Plus Metformin Versus ...“38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the ...”
{
"schema":"http://google-preview.miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"semaglutide-metformin",
"title":"semaglutide metformin",
"kind":"standard",
"summary":"Evidence is being populated by Grok web",
"created":"2026-06-29T17:31:34.058Z",
"body": [
"## Overview\nEvidence is being populated by Grok web search."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T17:32:34.856Z",
"register":"standard",
"category":null
},
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/39700591/",
"title":"The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease",
"quote":"The combination of semaglutide and metformin significantly improves liver inflammation, fibrosis, and beta-cell function in patients with T2DM and NAFLD",
"summary":"2025 study on benefits of semaglutide + metformin combo for liver inflammation, fibrosis, and beta-cell function in T2DM with NAFLD.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:34.180Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"genesis",
"hash":"939c1ba518ca0aacc5a303cfb560db00ed2189d3a2eabc6c9ad908f7ee46a528",
"quote_sha256":"c5445ae4e12ac3d6ab344a97944e47e8e9991a0875a3a1a60e14d099a0ca98d8"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40713699/",
"title":"Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial",
"quote":"Compared to MET monotherapy, combination therapy with semaglutide and MET significantly reduced body weight, improved insulin resistance, decreased ...",
"summary":"2025 RCT showing semaglutide + metformin superior to metformin alone for weight, insulin resistance, and reproductive outcomes in PCOS.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:34.180Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"939c1ba518ca0aacc5a303cfb560db00ed2189d3a2eabc6c9ad908f7ee46a528",
"hash":"a5730eab2acedbf01543c049a95129ca5c5c9e48ac94177f905e1ef844d39969",
"quote_sha256":"a13cdddab60db8d29f71516b5eef9cf8196dc2c9560ad07a2140c1daf4b5fbe9"
},
{
"id":"s3",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/39796271/",
"title":"Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study",
"quote":"The results indicate that combining 1 mM metformin with either 10 nM semaglutide or 10 nM tirzepatide significantly enhances the effects of 10 nM semaglutide",
"summary":"2025 in vitro study on enhanced effects of semaglutide + metformin combo on beta-cell function under stress.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:34.180Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"a5730eab2acedbf01543c049a95129ca5c5c9e48ac94177f905e1ef844d39969",
"hash":"3f0978346b3c23bfcfcbd50125951f64c3bfdfb540f240392532a44d0096b6f5",
"quote_sha256":"1e2507774451c57ba5d32997a05badde652e0472e1836fa15ba4e4d305842655"
},
{
"id":"s4",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/42026662/",
"title":"Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)",
"quote":"Generic semaglutide demonstrated non-inferior efficacy and comparable safety to innovator Semaglutide in Indian adults with T2DM inadequately controlled on metformin",
"summary":"2026 phase 3 trial of semaglutide add-on to metformin in Indian T2DM patients showing non-inferiority.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:34.180Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"3f0978346b3c23bfcfcbd50125951f64c3bfdfb540f240392532a44d0096b6f5",
"hash":"e4ab26a846164f90d040c14753a80f9834a4e7b7f4687d5aee52cfdec78592b1",
"quote_sha256":"ff542986315bd3edde9bee9925d07ba0e2e0d1a6c48a6d464a4f0606ab9ec3f8"
},
{
"id":"s5",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41421448/",
"title":"Effect of semaglutide with metformin for weight loss and ...",
"quote":"In this study , we demonstrated a significant efficacy of combined treatment with subcutaneous semaglutide and metformin in effective weight reduction and ...",
"summary":"Demonstrates significant efficacy of combined subcutaneous semaglutide and metformin for weight reduction.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:52.940Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e4ab26a846164f90d040c14753a80f9834a4e7b7f4687d5aee52cfdec78592b1",
"hash":"ac8e4f93cc5d67c878aa5ac170c585f907e44e7d56c6191749bfabbb7ff83e1e",
"quote_sha256":"4ce68cd85821e29bc707b9c5dfdbaab8933a8ec460840a294f0714b3fb0fd056"
},
{
"id":"s6",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41893436/",
"title":"Semaglutide Plus Low-Dose Metformin Combination ...",
"quote":"At 5 months after initiation of the combination therapy, blood tests showed metabolic improvements, including improvement of prediabetes (0.3- ...",
"summary":"Reports metabolic improvements including prediabetes resolution with semaglutide plus low-dose metformin combination at 5 months.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:52.940Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"ac8e4f93cc5d67c878aa5ac170c585f907e44e7d56c6191749bfabbb7ff83e1e",
"hash":"f0a97ce15b9312a5a1b14ff5c1641cc38c5fa34c5eff37c271a8eddb99ab7a66",
"quote_sha256":"68ae2de162c1b3aa71758e7cb20f2515acc264a40d637d75b14e73ff2f99c2a2"
},
{
"id":"s7",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40227520/",
"title":"Semaglutide Plus Metformin Versus ...",
"quote":"38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the ...",
"summary":"Compares semaglutide plus metformin vs monotherapy, showing higher rate of ≥5% weight loss in combination group.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:31:52.940Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"f0a97ce15b9312a5a1b14ff5c1641cc38c5fa34c5eff37c271a8eddb99ab7a66",
"hash":"32f4801c20eb315f661980715df265ed9468bf6f83abdab1ab048a3ff42dd59e",
"quote_sha256":"d442d66586ed742da5bf0070b2236ec3be3fe3d03e7304ca963722bacbe1834c"
},
{
"id":"s8",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41765029/",
"title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial",
"quote":"This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individuals with type 2 diabetes inadequately controlled with metformin.",
"summary":"Phase 3 trial comparing orforglipron to oral semaglutide in T2D patients on metformin background; orforglipron showed non-inferiority and superiority in HbA1c reduction.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:32:33.794Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"32f4801c20eb315f661980715df265ed9468bf6f83abdab1ab048a3ff42dd59e",
"hash":"0e64e41d0b32894c7226e83c200352df0ba4bf86f9f294dbb63b593993d47634",
"quote_sha256":"2e94ad3c48b932184e5917a4775cd2f32719213f4215a2e4843881d0f70bd278"
},
{
"id":"s9",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/42251859/",
"title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study",
"quote":"Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more",
"summary":"CagriSema (cagrilintide + semaglutide) superior to semaglutide alone for HbA1c reduction in T2D patients on metformin ± SGLT2i.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:32:33.794Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"0e64e41d0b32894c7226e83c200352df0ba4bf86f9f294dbb63b593993d47634",
"hash":"741b950d596f7752c8d2effec247b1314ddebfc472f53485549f782e34ef8898",
"quote_sha256":"e05188cb8b787e502ad4c189bda34d892300dbda77e22ae406e5b3215bdbf9e1"
},
{
"id":"s10",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/42219226/",
"title":"Semaglutide Injection in Indian Patients With Type 2 Diabetes Inadequately Controlled on Metformin",
"quote":"... metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once ...",
"summary":"Phase 3 trial of generic vs reference semaglutide in Indian T2D patients on metformin; non-inferior efficacy and safety.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:32:33.794Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"741b950d596f7752c8d2effec247b1314ddebfc472f53485549f782e34ef8898",
"hash":"2396853afc0308d991d3328abca52a25f51f9e46089d1a9fed9cb562580f742c",
"quote_sha256":"7ba8cd10f039894d42097870f6360039e5a7bf2336e388942b2ee37f3cff16aa"
},
{
"id":"s11",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41715123/",
"title":"Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a systematic review and network meta-analysis",
"quote":"2.4 mg of semaglutide SC and 15 mg of tirzepatide were the best option among the included interventions considering favorable glucose and BMI control.",
"summary":"Network meta-analysis including semaglutide and metformin in prediabetes; semaglutide 2.4mg optimal for weight loss and HbA1c.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:32:33.794Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"2396853afc0308d991d3328abca52a25f51f9e46089d1a9fed9cb562580f742c",
"hash":"0269fe9329cee434595cf3a572ec66d7f0154ae12524b6220e8c2b305d3afdaa",
"quote_sha256":"d9d5fcfd891ace855aba5a7f571b65066ca1e42e6a469c8467458f293ca5a0cc"
}
],
"type":"article",
"updated":"2026-10-08T11:49:33.889Z",
"version":1,
"hash":"d0028e678d0f7be122ba93a18d8fed3569f293dd0218c52339dd2039f82e9e20",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH http://google-preview.miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"http://google-preview.miscsubjects.com/a/semaglutide-metformin",
"json":"http://google-preview.miscsubjects.com/a/semaglutide-metformin.json",
"markdown":"http://google-preview.miscsubjects.com/a/semaglutide-metformin.md",
"theme":"http://google-preview.miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-metformin",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-metformin.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-metformin.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"semaglutide-metformin",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"semaglutide-metformin"
}
}
]
}